{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T01:03:32Z","timestamp":1784855012695,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fundamental Research Funds for the Central Universities, Peking Union Medical College","award":["3332024077"],"award-info":[{"award-number":["3332024077"]}]},{"name":"Tianjin Municipal Science and Technology Commission Grant","award":["25ZXRKSY00040"],"award-info":[{"award-number":["25ZXRKSY00040"]}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2024YFC2510500"],"award-info":[{"award-number":["2024YFC2510500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Sciences Foundation of China","doi-asserted-by":"crossref","award":["82470208"],"award-info":[{"award-number":["82470208"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Research Fund for Clinical Application of Amphotericin B Antifungal Agents","award":["KC2024-JX-0092-1"],"award-info":[{"award-number":["KC2024-JX-0092-1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13653-4","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T05:45:02Z","timestamp":1779860702000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multidrug-resistant Acinetobacter spp. bloodstream infections in hematologic patients: clinical characteristics, genomic features, and eravacycline-based combination therapy"],"prefix":"10.1186","volume":"26","author":[{"given":"Wenjing","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuobing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yigeng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiming","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhou","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sizhou","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"13653_CR1","doi-asserted-by":"crossref","unstructured":"Kim SH, Mun SJ. Comparative analysis of clinical characteristics and antimicrobial resistance between acinetobacter baumannii and other acinetobacter species. Pathogens. 2025;14(1).","DOI":"10.3390\/pathogens14010046"},{"issue":"13","key":"13653_CR2","doi-asserted-by":"publisher","first-page":"e14937","DOI":"10.1097\/MD.0000000000014937","volume":"98","author":"H Zhou","year":"2019","unstructured":"Zhou H, Yao Y, Zhu B, Ren D, Yang Q, Fu Y, et al. Risk factors for acquisition and mortality of multidrug-resistant Acinetobacter baumannii bacteremia: A retrospective study from a Chinese hospital. Med (Baltim). 2019;98(13):e14937.","journal-title":"Med (Baltim)"},{"key":"13653_CR3","doi-asserted-by":"crossref","unstructured":"Yu H, Hu R, Hu X, Lu Y, Yao Y, Su J. Risk factors for bacteremia and mortality due to multidrug-resistant Acinetobacter baumannii: a retrospective study. Lett Appl Microbiol. 2024;77(2).","DOI":"10.1093\/lambio\/ovae006"},{"issue":"Suppl 2","key":"13653_CR4","doi-asserted-by":"publisher","first-page":"S166","DOI":"10.1093\/cid\/ciad109","volume":"76","author":"M Castanheira","year":"2023","unstructured":"Castanheira M, Mendes RE, Gales AC. Global Epidemiology and Mechanisms of Resistance of Acinetobacter baumannii-calcoaceticus Complex. Clin Infect Dis. 2023;76(Suppl 2):S166\u201378.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"13653_CR5","doi-asserted-by":"publisher","first-page":"e0087224","DOI":"10.1128\/spectrum.00872-24","volume":"13","author":"AS Shahari","year":"2024","unstructured":"Shahari AS, Palanisamy NK, Mohd Nor F. Genetic profiling of multidrug-resistant Acinetobacter baumannii from a tertiary care center in Malaysia. Microbiol Spectr. 2024;13(2):e0087224.","journal-title":"Microbiol Spectr"},{"issue":"11","key":"13653_CR6","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1128\/AAC.01288-13","volume":"57","author":"JA Sutcliffe","year":"2013","unstructured":"Sutcliffe JA, O\u2019Brien W, Fyfe C, Grossman TH. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013;57(11):5548\u201358.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"13653_CR7","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1128\/AAC.02036-13","volume":"58","author":"KP Connors","year":"2014","unstructured":"Connors KP, Housman ST, Pope JS, Russomanno J, Salerno E, Shore E, et al. Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. Antimicrob Agents Chemother. 2014;58(4):2113\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"13653_CR8","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jgar.2023.04.017","volume":"33","author":"S Hawser","year":"2023","unstructured":"Hawser S, Kothari N, Monti F, Morrissey I, Siegert S, Hodges T. In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020. J Glob Antimicrob Resist. 2023;33:304\u201320.","journal-title":"J Glob Antimicrob Resist"},{"issue":"8","key":"13653_CR9","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41429-019-0188-6","volume":"72","author":"HS Ozger","year":"2019","unstructured":"Ozger HS, Cuhadar T, Yildiz SS, Demirbas Gulmez Z, Dizbay M, Guzel Tunccan O, et al. In vitro activity of eravacycline in combination with colistin against carbapenem-resistant A. baumannii isolates. J Antibiot (Tokyo). 2019;72(8):600\u20134.","journal-title":"J Antibiot (Tokyo)"},{"key":"13653_CR10","doi-asserted-by":"crossref","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious diseases society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis. 2024.","DOI":"10.1093\/cid\/ciae403"},{"issue":"4","key":"13653_CR11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2021","unstructured":"Paul M, Carrara E, Retamar P, T\u00e4ngd\u00e9n T, Bitterman R, Bonomo RA, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2021;28(4):521\u201347.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"13653_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40265-024-02104-6","volume":"85","author":"A Iovleva","year":"2024","unstructured":"Iovleva A, Fowler VG, Doi Y. Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections. Drugs. 2024;85(1):21\u201340.","journal-title":"Drugs"},{"issue":"1","key":"13653_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13756-020-00876-6","volume":"10","author":"K Yu","year":"2021","unstructured":"Yu K, Zeng W, Xu Y, Liao W, Xu W, Zhou T, et al. Bloodstream infections caused by ST2 Acinetobacter baumannii: risk factors, antibiotic regimens, and virulence over 6 years period in China. Antimicrob Resist Infect Control. 2021;10(1):16.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"1","key":"13653_CR14","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1186\/s12879-023-08789-6","volume":"23","author":"J Li","year":"2023","unstructured":"Li J, Feng X, Wang J, Lin Q, Zheng Y, Zhang F, et al. Acinetobacter spp. bloodstream infection in hematological patients: a 10-year single-center study. BMC Infect Dis. 2023;23(1):796.","journal-title":"BMC Infect Dis"},{"key":"13653_CR15","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.2147\/IDR.S458427","volume":"17","author":"J Li","year":"2024","unstructured":"Li J, Guo W, Wang J, Feng X, Lin Q, Zheng Y, et al. Strong Homology Between Colonizing and Bloodstream Carbapenem-Resistant Acinetobacter Spp.: Implications for Empiric Antibiotic Therapy in Hematological Patients. Infect Drug Resist. 2024;17:1827\u201338.","journal-title":"Infect Drug Resist"},{"issue":"3","key":"13653_CR16","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2011","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2011;18(3):268\u201381.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"13653_CR17","doi-asserted-by":"publisher","first-page":"e0101124","DOI":"10.1128\/spectrum.01011-24","volume":"13","author":"W Guo","year":"2025","unstructured":"Guo W, Lin Q, Li J, Feng X, Zhen S, Mi Y, et al. Stenotrophomonas maltophilia bacteremia in adult patients with hematological diseases: clinical characteristics and risk factors for 28-day mortality. Microbiol Spectr. 2025;13(1):e0101124.","journal-title":"Microbiol Spectr"},{"issue":"3","key":"13653_CR18","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jinf.2011.12.008","volume":"64","author":"H Wisplinghoff","year":"2011","unstructured":"Wisplinghoff H, Paulus T, Lugenheim M, Stefanik D, Higgins PG, Edmond MB, et al. Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States. J Infect. 2011;64(3):282\u201390.","journal-title":"J Infect"},{"issue":"1","key":"13653_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkg301","volume":"52","author":"FC Odds","year":"2003","unstructured":"Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003;52(1):1.","journal-title":"J Antimicrob Chemother"},{"key":"13653_CR20","doi-asserted-by":"crossref","unstructured":"Wyres KL, Cahill SM, Holt KE, Hall RM, Kenyon JJ. Identification of Acinetobacter baumannii loci for capsular polysaccharide (KL) and lipooligosaccharide outer core (OCL) synthesis in genome assemblies using curated reference databases compatible with Kaptive. Microb Genom. 2020;6(3).","DOI":"10.1099\/mgen.0.000339"},{"issue":"D1","key":"13653_CR21","doi-asserted-by":"publisher","first-page":"D690","DOI":"10.1093\/nar\/gkac920","volume":"51","author":"BP Alcock","year":"2023","unstructured":"Alcock BP, Huynh W, Chalil R, Smith KW, Raphenya AR, Wlodarski MA, et al. CARD 2023: expanded curation, support for machine learning, and resistome prediction at the Comprehensive Antibiotic Resistance Database. Nucleic Acids Res. 2023;51(D1):D690\u20139.","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"13653_CR22","doi-asserted-by":"publisher","first-page":"D325","DOI":"10.1093\/nar\/gki008","volume":"33","author":"L Chen","year":"2005","unstructured":"Chen L, Yang J, Yu J, Yao Z, Sun L, Shen Y, et al. VFDB: a reference database for bacterial virulence factors. Nucleic Acids Res. 2005;33(Database issue):D325\u20138.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"13653_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ijantimicag.2011.08.016","volume":"39","author":"H-Y Kuo","year":"2011","unstructured":"Kuo H-Y, Chang K-C, Kuo J-W, Yueh H-W, Liou M-L. Imipenem: a potent inducer of multidrug resistance in Acinetobacter baumannii. Int J Antimicrob Agents. 2011;39(1):33\u20138.","journal-title":"Int J Antimicrob Agents"},{"key":"13653_CR24","doi-asserted-by":"crossref","unstructured":"Al-Tamimi M, Albalawi H, Alkhawaldeh M, Alazzam A, Ramadan H, Altalalwah M, et al. Multidrug-resistant acinetobacter baumannii in Jordan. Microorganisms. 2022;10(5).","DOI":"10.3390\/microorganisms10050849"},{"issue":"6","key":"13653_CR25","doi-asserted-by":"publisher","first-page":"e0319924","DOI":"10.1128\/spectrum.03199-24","volume":"13","author":"MS Linz","year":"2025","unstructured":"Linz MS, Collins L, Keenan E, Biswas R, Levine D, Mattappallil A, et al. Biological sex influences severity and outcomes in Acinetobacter baumannii pneumonia. Microbiol Spectr. 2025;13(6):e0319924.","journal-title":"Microbiol Spectr"},{"issue":"8","key":"13653_CR26","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.ajic.2018.04.231","volume":"46","author":"W-L Yuan","year":"2018","unstructured":"Yuan W-L, Shen Y-J, Deng D-Y. Sex bias of Acinetobacter baumannii nosocomial infection. Am J Infect Control. 2018;46(8):957\u20138.","journal-title":"Am J Infect Control"},{"issue":"4","key":"13653_CR27","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.cmi.2015.12.010","volume":"22","author":"MP Freire","year":"2015","unstructured":"Freire MP, de Oliveira Garcia D, Garcia CP, Campagnari Bueno MF, Camargo CH, Kono Magri ASG, et al. Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia. Clin Microbiol Infect. 2015;22(4):352\u20138.","journal-title":"Clin Microbiol Infect"},{"key":"13653_CR28","doi-asserted-by":"crossref","unstructured":"Beganovic M, Daffinee KE, Luther MK, LaPlante KL. Minocycline alone and in combination with polymyxin B, meropenem, and sulbactam against carbapenem-susceptible and -resistant acinetobacter baumannii in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2021;65(3).","DOI":"10.1128\/AAC.01680-20"},{"key":"13653_CR29","doi-asserted-by":"crossref","unstructured":"Chopjitt P, Putthanachote N, Ungcharoen R, Hatrongjit R, Boueroy P, Akeda Y, et al. Genomic characterization of clinical extensively drug-resistant acinetobacter pittii isolates. Microorganisms. 2021;9(2).","DOI":"10.3390\/microorganisms9020242"},{"key":"13653_CR30","doi-asserted-by":"crossref","unstructured":"Sheck E, Romanov A, Shapovalova V, Shaidullina E, Martinovich A, Ivanchik N, et al. Acinetobacter non-baumannii species: occurrence in infections in hospitalized patients, identification, and antibiotic resistance. Antibiot (Basel). 2023;12(8).","DOI":"10.3390\/antibiotics12081301"},{"issue":"2","key":"13653_CR31","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/cid\/ciad556","volume":"78","author":"M Wang","year":"2024","unstructured":"Wang M, Ge L, Chen L, Komarow L, Hanson B, Reyes J, et al. Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions. Clin Infect Dis. 2024;78(2):248\u201358.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"13653_CR32","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1038\/s41467-025-58772-9","volume":"16","author":"Q Luo","year":"2025","unstructured":"Luo Q, Chang M, Lu P, Guo Q, Jiang X, Xiao T, et al. Genomic epidemiology and phylodynamics of Acinetobacter baumannii bloodstream isolates in China. Nat Commun. 2025;16(1):3536.","journal-title":"Nat Commun"},{"key":"13653_CR33","doi-asserted-by":"publisher","first-page":"8168000","DOI":"10.1155\/2022\/8168000","volume":"2022","author":"M Kumari","year":"2022","unstructured":"Kumari M, Bhattarai NR, Rai K, Pandit TK, Khanal B, Multidrug-Resistant, Acinetobacter. Detection of ESBL, MBL, bla NDM-1 Genotype, and Biofilm Formation at a Tertiary Care Hospital in Eastern Nepal. Int J Microbiol. 2022;2022:8168000.","journal-title":"Int J Microbiol"},{"issue":"6","key":"13653_CR34","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3855\/jidc.19119","volume":"18","author":"M Arif","year":"2024","unstructured":"Arif M, Asif A, Nazeer K, Sultan S, Riaz S. Coexistence of \u03b2-lactamase genes and biofilm forming potential among carbapenem-resistant Acinetobacter baumannii in Lahore, Pakistan. J Infect Dev Ctries. 2024;18(6):943\u20139.","journal-title":"J Infect Dev Ctries"},{"key":"13653_CR35","doi-asserted-by":"crossref","unstructured":"Ramirez MS, Bonomo RA, Tolmasky ME. Carbapenemases: Transforming Acinetobacter baumannii into a Yet More Dangerous Menace. Biomolecules. 2020;10(5).","DOI":"10.3390\/biom10050720"},{"key":"13653_CR36","doi-asserted-by":"publisher","first-page":"1439373","DOI":"10.3389\/fmicb.2024.1439373","volume":"15","author":"DCS Rodrigues","year":"2024","unstructured":"Rodrigues DCS, Silveira MC, Pribul BR, Karam BRS, Pic\u00e3o RC, Kraychete GB, et al. Genomic study of Acinetobacter baumannii strains co-harboring bla OXA-58 and bla NDM-1 reveals a large multidrug-resistant plasmid encoding these carbapenemases in Brazil. Front Microbiol. 2024;15:1439373.","journal-title":"Front Microbiol"},{"key":"13653_CR37","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.2147\/IDR.S459739","volume":"17","author":"IK Bae","year":"2024","unstructured":"Bae IK, Hong JS. The Distribution of Carbapenem-Resistant Acinetobacter Species and High Prevalence of CC92 OXA-23-Producing Acinetobacter Baumannii in Community Hospitals in South Korea. Infect Drug Resist. 2024;17:1633\u201341.","journal-title":"Infect Drug Resist"},{"issue":"3","key":"13653_CR38","doi-asserted-by":"publisher","first-page":"332","DOI":"10.29271\/jcpsp.2020.03.332","volume":"30","author":"Q Lv","year":"2020","unstructured":"Lv Q, Deng Y, Zhu X, Ruan J, Chen L. Effectiveness of Cefoperazone-sulbactam alone and Combined with Tigecycline in the Treatment of Multi-drug Resistant Acinetobacter Baumannii Pulmonary Infection. J Coll Physicians Surg Pak. 2020;30(3):332\u20134.","journal-title":"J Coll Physicians Surg Pak"},{"issue":"06","key":"13653_CR39","first-page":"693","volume":"48","author":"\u4e2d\u56fd\u533b\u9662\u534f\u4f1a\u4e34\u5e8a\u5fae\u751f\u7269\u5b9e\u9a8c\u5ba4\u4e13\u4e1a\u59d4\u5458\u4f1a \u56fd\u5bb6\u536b\u751f\u5065\u5eb7\u59d4\u4e34\u5e8a\u6297\u5fae\u751f\u7269\u836f\u7269\u654f\u611f\u6027\u6298\u70b9\u7814\u7a76\u548c\u6807\u51c6\u5236\u5b9a\u4e13\u5bb6\u59d4\u5458\u4f1a","year":"2025","unstructured":"\u56fd\u5bb6\u536b\u751f\u5065\u5eb7\u59d4\u4e34\u5e8a\u6297\u5fae\u751f\u7269\u836f\u7269\u654f\u611f\u6027\u6298\u70b9\u7814\u7a76\u548c\u6807\u51c6\u5236\u5b9a\u4e13\u5bb6\u59d4\u5458\u4f1a \u4e2d\u56fd\u533b\u9662\u534f\u4f1a\u4e34\u5e8a\u5fae\u751f\u7269\u5b9e\u9a8c\u5ba4\u4e13\u4e1a\u59d4\u5458\u4f1a. \u6b27\u6d32\u4e34\u5e8a\u5fae\u751f\u7269\u4e0e\u611f\u67d3\u75c5\u5b66\u4f1a\u836f\u654f\u59d4\u5458\u4f1a\u534e\u4eba\u836f\u654f\u8bd5\u9a8c\u59d4\u5458\u4f1a. \u4f9d\u62c9\u73af\u7d20\u4f53\u5916\u836f\u7269\u654f\u611f\u6027\u8bd5\u9a8c\u89c4\u8303 (2025). \u4e2d\u534e\u68c0\u9a8c\u533b\u5b66\u6742\u5fd7. 2025;48(06):693\u2013700.","journal-title":"\u4e2d\u534e\u68c0\u9a8c\u533b\u5b66\u6742\u5fd7"},{"issue":"3","key":"13653_CR40","doi-asserted-by":"publisher","first-page":"e0128725","DOI":"10.1128\/aac.01287-25","volume":"70","author":"J Wang","year":"2026","unstructured":"Wang J, Zhu J, Wu W, Luo R, Liu Z, Tong Z, et al. Clinical outcomes and safety of eravacycline in hematology: a multicenter, real-world study. Antimicrob Agents Chemother. 2026;70(3):e0128725.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"13653_CR41","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/cid\/ciy988","volume":"69","author":"Y Dickstein","year":"2019","unstructured":"Dickstein Y, Lellouche J, Ben Dalak Amar M, Schwartz D, Nutman A, Daitch V, et al. Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial. Clin Infect Dis. 2019;69(5):769\u201376.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"13653_CR42","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/clinids\/24.3.494","volume":"24","author":"JD Williams","year":"1997","unstructured":"Williams JD. beta-Lactamase inhibition and in vitro activity of sulbactam and sulbactam\/cefoperazone. Clin Infect Dis. 1997;24(3):494\u20137.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"13653_CR43","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1128\/AAC.04808-14","volume":"59","author":"WF Penwell","year":"2015","unstructured":"Penwell WF, Shapiro AB, Giacobbe RA, Gu R-F, Gao N, Thresher J, et al. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob Agents Chemother. 2015;59(3):1680\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4 Suppl","key":"13653_CR44","doi-asserted-by":"publisher","first-page":"S139","DOI":"10.1016\/0732-8893(89)90126-0","volume":"12","author":"A Kazmierczak","year":"1989","unstructured":"Kazmierczak A, Pechinot A, Siebor E, Cordin X, Labia R. Sulbactam: secondary mechanisms of action. Diagn Microbiol Infect Dis. 1989;12(4 Suppl):S139\u201346.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"13653_CR45","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1179\/1973947814Y.0000000203","volume":"27","author":"B Liu","year":"2014","unstructured":"Liu B, Bai Y, Liu Y, Di X, Zhang X, Wang R, et al. In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii. J Chemother. 2014;27(5):271\u20136.","journal-title":"J Chemother"},{"issue":"12","key":"13653_CR46","doi-asserted-by":"publisher","first-page":"7236","DOI":"10.1128\/AAC.01669-16","volume":"60","author":"S Jaruratanasirikul","year":"2016","unstructured":"Jaruratanasirikul S, Wongpoowarak W, Wattanavijitkul T, Sukarnjanaset W, Samaeng M, Nawakitrangsan M, et al. Population Pharmacokinetics and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60(12):7236\u201344.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"13653_CR47","doi-asserted-by":"publisher","first-page":"e0188024","DOI":"10.1128\/aac.01880-24","volume":"69","author":"J Lee","year":"2025","unstructured":"Lee J, Lee I, Lee K-B, Lee SS. Comparative effectiveness and safety of colistin-based versus high-dose ampicillin\/sulbactam-based combination therapy for nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2025;69(6):e0188024.","journal-title":"Antimicrob Agents Chemother"},{"key":"13653_CR48","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jgar.2020.08.021","volume":"24","author":"J Liu","year":"2020","unstructured":"Liu J, Shu Y, Zhu F, Feng B, Zhang Z, Liu L, et al. Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis. J Glob Antimicrob Resist. 2020;24:136\u201347.","journal-title":"J Glob Antimicrob Resist"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13653-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13653-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13653-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:45:15Z","timestamp":1784853915000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13653-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13653"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13653-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. Ethical approval was obtained from the Ethics Committee of the Blood Diseases Hospital, Chinese Academy of Medical Sciences. Lot number: IIT2021011-EC-1. All procedures involving human participants were performed in accordance with the ethical standards of the institutional research committee. Written informed consent was obtained from all participants or their legal guardians before sample collection.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1390"}}